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We investigated whether Merkel cell carcinoma (MCC) 
patients in France carry Merkel cell polyomavirus (MCPyV) 
and then identified strain variations. All frozen MCC speci-
mens  and  45%  of  formalin-fixed  and  paraffin-embedded 
specimens, but none of the non-MCC neuroendocrine car-
cinomas specimens, had MCPyV. Strains from France and 
the United States were similar.
A
lthough  infectious  agents  have  been  recognized  as 
etiologic agents in ≈20% of cancers (1), the list of on-
cogenic infectious agents is limited. A new virus, Merkel 
cell polyomavirus (MCPyV), recently was discovered in 
humans with Merkel cell carcinoma (MCC), a relatively 
rare, aggressive primary cutaneous neuroendocrine carci-
noma. Feng et al. (2) reported PCR detection of MCPyV 
in most MCC specimens (2), and clonal integration of the 
viral genome has been identified.
Polyomaviruses are small nonenveloped DNA viruses, 
with a double-stranded circular DNA genome of ≈5 kb pack-
aged within a capsid 45–50 nm in diameter and composed 
of 3 proteins: VP1, VP2, and VP3 (3). Twenty members of 
the polyomavirus family have been identified in mammals 
and birds (4). Four viruses, including the ubiquitous BK 
and JC viruses, which cause persistent or latent infections, 
infect humans. Although BK virus, JC virus, and simian 
virus 40 are tumorigenic in experimental animals and can 
transform mammalian cells in vitro, no convincing epide-
miologic evidence exists for their role in human cancers. 
We investigated whether patients in France who had MCC 
carry MCPyV and aimed to identify the strain variations.
The Study
We conducted our study in 2008 on samples collected 
during 1991–2008. The study comprised 39 patients with 
MCC (50–93 years of age, mean 76.9 years; sex ratio 0.95 
[19 men, 20 women]). Formalin-fixed and paraffin-embed-
ded (FFPE) tissue specimens from 27 patients and frozen 
resection specimens from 12 other patients were investi-
gated for MCPyV. In addition, frozen tissue from 8 patients 
with non-MCC high-grade neuroendocrine carcinomas (5 
small-cell  lung  carcinomas  and  3  well-differentiated  in-
testinal carcinomas) and an FFPE tissue specimen from a 
patient with high-grade neuroendocrine carcinoma of the 
cervix  (human  papillomavirus  16  DNA  positive)  were 
investigated for MCPyV (43–79 years of age, mean 54.0 
years; sex ratio 0.80). All tissue samples were collected for 
diagnostic purposes, and participants gave written consent 
in accordance with French ethics regulations.
For DNA preparation from FFPE tissues, 8–10 consec-
utive sections were subjected to deparaffinization, tissues 
were then lysed by proteinase K, and DNA was purified by 
phenol-chloroform extraction. For DNA preparation from 
frozen specimens, tissue was directly treated with protei-
nase K and processed as above.
MCPyV was detected by nested PCR by using a first 
PCR  amplification  with  the  LT1  and  VP1  primer  sets 
published by Feng et al. (2). PCR was performed with 31 
cycles for each primer set. A second run of amplification 
was performed with 2 nested pairs of primers (LT1n, for-
ward  5′-GGCATGCCTGTGAATTAGGA-3′  and  reverse 
5′-TGTAAGGGGGCTTGCATAAA-3′;  and  VP1n,  for-
ward  5′-TGCAAATCCAGAGGTTCTCC-3′  and  reverse 
5′-GCAGATGTGGGAGGCAATA-3′)  with  PCR  prod-
ucts from the first round of amplification. Amplification 
products were subjected to electrophoresis, stained with 
ethidium bromide, and examined under UV light. To avoid 
false-negative  results  from  unsuitable  DNA  quality,  a 
seminested PCR with β-globin primers was run. The first 
PCR was performed with primers PC04/GH20, and the sec-
ond PCR used primers PC04/PC03 (5). Water was used as 
PCR-negative controls, and a DNA extract from frozen tis-
sue from an MCC patient was used as a positive control in 
all experiments. β-Globin amplicons were observed for all 
frozen MCC tissues investigated (sex ratio 1.0; mean age 
71.3 years), whereas only 20 (74%) of 27 FFPE MCC tis-
sues were positive for β-globin by PCR. We found no sta-
tistically significant differences in sex ratio and mean age 
between patients with samples that were FFPE β-globin 
positive (sex ratio 0.73, mean age 78.5 years) and those 
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that were β-globin negative (sex ratio 0.75; mean age 82.1 
years). β-Globin amplicons were detected in all patients 
with non-MCC neuroendocrine carcinoma (sex ratio 0.86; 
mean age 60.4 years).
Samples from 21 (66%) of the 32 β-globin–positive 
MCC patients were PCR positive for MCPyV (Table). All 
12 frozen samples of MCC were MCPyV DNA positive, 
in contrast to FFPE MCC samples in which MCPyV was 
detected in only 9 (45%) of the 20 investigated. This low 
level of detection is similar to the 43% reported by Gar-
neski et al. (6) and the 54% reported by Ridd et al. (7), but 
lower than the 85% reported by Becker et al. (8) in which 
a smaller DNA segment (80 bp) was amplified by using 
quantitative PCR. Identity of the PCR products was veri-
fied by sequencing or Southern blotting (data not shown). 
For this purpose, 1 LT1- and 1 VP1-nested PCR products 
were cloned, sequenced, and used to prepare digoxygenin-
labeled probes. VP1 amplicons of ≈350 bp were observed 
after the first PCR amplification in 9 of the frozen samples 
from 12 MCC patients. Amplicons of smaller size (≈250 
bp) corresponding to a 90-bp deletion in the VP1 open 
reading frame, as observed by Kassem et al. (9) in 1 of 14 
patients, were not detected. In contrast, MCPyV DNA was 
not detected for any of the 9 patients with non-MCC neu-
roendocrine carcinomas (Table).
In addition, we investigated the possibility of amplify-
ing the entire VP1 open reading frame by encoding the major 
capsid  protein  of  MCPyV,  using  VP1F/VP1R  primer  sets  (5′-
CCTGAATTACAAGTAATTGAAGATGGCACC-3′ and 
5′-CTGAATAGGAATGCATGAAATAATTCTCAT-3′, 
respectively). The VP1 gene was amplified from 7 of the 
frozen  samples  (online  Technical  Appendix,  available 
from  www.cdc.gov/EID/content/15/6/960-Techapp.pdf), 
and 6 of these VP1 amplicons of ≈1,300 bp were cloned 
and then sequenced. We compared the sequences obtained 
with the MCPyV sequences from isolates from the Unit-
ed States, Sweden, and Japan (MCC339, EU375804.1; 
MCC350,  EU375803.1;  MKL-1,  FJ173815;  and  TKS, 
FJ464337). The results confirmed the MCPyV VP1 se-
quence, and only point mutations were observed in the 
VP1 sequences from the isolates from France compared 
with the VP1 sequences published (online Technical Ap-
pendix). The VP1 amino acid sequence from 4 French 
isolates of MCPyV was identical to that of the Swedish 
MKL-1 isolate (10), and 1 (MKT-23) was identical to that 
of the MCC339 strain (2). MKT-26 showed 2 point muta-
tions that were not reported in any of the other isolates. No 
French isolate was similar to the U.S. strain MCC350 (2), 
nor to the recently described Japanese isolate (FJ464337). 
Moreover, 3 silent nucleotide changes were observed in 
all French isolates, compared with the MCC339 strain, 
and 1–4 different silent point mutations were observed 
in isolates MKT-21, MKT-23, MKT-26, MKT-31, and 
MKT-33.
Because deletions in the viral genome have been re-
ported in the VP2 sequence and the regulatory region of 
hamster polyomavirus (11), a virus that causes lympho-
mas, the sequence encompassing part of the VP2 protein 
and the regulatory region (4,876–238) of 7 MCPyV iso-
lates were PCR amplified with the primer set RegF/RegR 
(5′-TGTTCAGCTGTGAACCCAAG-3′  and  5′-GAGC 
CTCTCTTTCTTTCCTATTT-3′,  respectively),  cloned, 
and sequenced. The N-terminal part of the VP2 of the 
French isolates was similar to those of the MCC339 U.S. 
strain and the MKL-1 Swedish strain and differed by 1 
amino acid (E41D) from that of the MCC350 U.S. strain. 
Only minor nucleotide changes were observed within the 
regulatory region in comparison with the MCC339 strain, 
except for a deletion of 5 bp (5022–5026) in 5 of the 7 
French isolates (online Technical Appendix). This dele-
tion has been reported in the MCC350 U.S. strain and the 
MKL-1 strain. The MKT-23 isolate was similar in the 
VP1, VP2, and regulatory region to the MCC350 strain.
Conclusions
Our study confirms the association of MCPyV with 
MCC (2,6,8,9,12). However, the primer sets used were not 
effective for detecting MCPyV DNA in FFPE tissues. In 
contrast, frozen tissues from MCC patients were all PCR 
positive, and the entire VP1 gene was easily amplified in 
7 of 12 MCC tissues. Our findings demonstrate that strains 
circulating in Europe are highly conserved and relatively 
similar to the MCC339 strain in the United States and the 
MKL-1 isolate from Sweden, suggesting this virus is ge-
netically stable. However, the VP1 sequence of these iso-
lates is relatively different from the VP1 sequence of the 
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Table. Detection of Merkel cell polyomavirus by PCR in patients with Merkel cell carcinoma using primers sets within LT and VP gene 
sequences, France, 2008* 
Sample No. patients LT1, no. (%) VP1, no. (%) Total, no. (%)
Merkel cell carcinoma
  Paraffin-embedded 20 6 (30) 6 (30) 9 (45)
  Frozen tissue 12 10 (83) 12 (100) 12 (100)
Other neuroendocrine carcinomas
  Paraffin-embedded 1 0 0 0
  Frozen tissue 8 0 0 0
*Non–Merkel cell carcinoma high-grade neuroendocrine carcinomas were 5 small-cell lung carcinomas, 3 well-differentiated intestinal carcinomas, and 1 
high-grade neuroendocrine carcinoma of the cervix. MCC350 strain identified in the United States. The MKT-
26  VP1  sequence,  isolated  from  an  80-year-old  MCC   
patient, differed from all other isolates.
MCC represents a promising direction for future stud-
ies. The MCPyV life cycle needs to be characterized and 
a greater understanding reached of the natural history of 
MCPyV infection in humans, including determination of 
whether MCPyV is associated with other human diseases 
or malignancies.
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